Cerulean Pharma Inc (NASDAQ:CERU) has been downgraded to Neutral in a statement by Janney Montgomery Scott earlier today.
- Updated: September 17, 2016
Showing a price of $1.14, Cerulean Pharma Inc (NASDAQ:CERU) traded 2.04% lower on the day. The last stock close is down 59.60% relative to the two hundred day average, compared with the S&P 500 which has fallen -0.01% over the same period. The company has recorded a 50-day average of $1.93 and two hundred day moving average of $2.40. 382,821 shares of Cerulean Pharma Inc traded hands, down from ann average trading volume of 541,442
Janney Montgomery Scott has downgraded Cerulean Pharma Inc(NASDAQ:CERU) to Neutral in a statement released 8/18/2016.
Previously on Thursday August 18 2016, Wedbush released a statement on Cerulean Pharma Inc(NASDAQ:CERU) lowered the target price from $9.00 to $1.00 that indicated a possible downside of -0.19%.
See Graphic Below:
A total of 7 firms have released a ratings update on Cerulean Pharma Inc. Four firms rate the stock a strong buy, three firms rate the company a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 analystsrate the company as sell with a one year target stock price of $9.43
With a market capitalization of $0.0, Cerulean Pharma Inc has a 52 week low of $0.95 and a 52 week high of $5.20 with a PE ratio of 0.
General Company Details For Cerulean Pharma Inc (NASDAQ:CERU)
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company’s product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, and which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.